ArticleBMC cardiovascular disorders2025
Apelin-to-total cholesterol ratio predicts long-term major adverse cardiovascular events in ST-elevation myocardial infarction patients after primary percutaneous coronary intervention: a retrospective cohort analysis.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TG/HDL-C Ratio as a Superior Diagnostic Biomarker for Coronary Plaque Burden in First-Time Acute Coronary Syndrome.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advancements in ST-segment elevation myocardial infarction (STEMI) management, residual risks of major adverse cardiovascular events (MACE) persist. Apelin, a cardioprotective peptide with anti-inflammatory properties, and total cholesterol (TC), a key atherogenic factor, may synergistically influence outcomes. This study evaluated the prognostic value of the Apelin/TC ratio for long-term MACEs in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
methodsA secondary analysis of 464 STEMI patients from a Chinese cohort was conducted. Patients were stratified by median Apelin/TC ratio (≥ 14 vs. < 14). Demographic, clinical, and laboratory data were analyzed. Cox regression models assessed associations between the Apelin/TC ratio and MACEs over 30 months. Receiver operator characteristic curve (ROC) determined predictive performance.
resultsThe cohort's median Apelin/TC ratio was 14. Patients with a ratio < 14 (n = 225) exhibited higher MACEs incidence (25.43% overall; p < 0.001) versus the high-ratio group (n = 239). Multivariable Cox models confirmed the Apelin/TC ratio as an independent predictor of MACEs (per 1 standard deviation increase: hazard ratios (HR) 0.437, 95% confidence intervals (CI) 0.305-0.627; categorical: HR 0.479, 95% CI 0.319-0.720, both p < 0.001). Survival curves demonstrated significant divergence (log-rank p < 0.001). ROC analysis revealed moderate predictive capacity (Area Under The Curve 0.64, 95% CI 0.58-0.69).
conclusionsA lower Apelin/TC ratio at admission independently predicted long-term MACEs in STEMI patients post-PCI, reflecting interplay between lipid burden and Apelin's cardioprotective effects. This ratio may enhance risk stratification by capturing dual metabolic and inflammatory pathways. Further validation is warranted to establish its clinical utility in guiding targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.